A condition characterized by recurring episodes of fluid leaking from capillaries into extra-vascular compartments causing hematocrit to rise precipitously. If not treated, generalized vascular leak can lead to generalized EDEMA; SHOCK; cardiovascular collapse; and MULTIPLE ORGAN FAILURE.
The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Process that is gone through in order for a device to receive approval by a government regulatory agency. This includes any required preclinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance. It is not restricted to FDA.

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. (1/91)

The dose-limiting toxicity of interleukin-2 (IL-2) and immunotoxin (IT) therapy in humans is vascular leak syndrome (VLS). VLS has a complex etiology involving damage to vascular endothelial cells (ECs), extravasation of fluids and proteins, interstitial edema, and organ failure. IL-2 and ITs prepared with the catalytic A chain of the plant toxin, ricin (RTA), and other toxins, damage human ECs in vitro and in vivo. Damage to ECs may initiate VLS; if this damage could be avoided without losing the efficacy of ITs or IL-2, larger doses could be administered. In this paper, we provide evidence that a three amino acid sequence motif, (x)D(y), in toxins and IL-2 damages ECs. Thus, when peptides from RTA or IL-2 containing this sequence motif are coupled to mouse IgG, they bind to and damage ECs both in vitro and, in the case of RTA, in vivo. In contrast, the same peptides with a deleted or mutated sequence do not. Furthermore, the peptide from RTA attached to mouse IgG can block the binding of intact RTA to ECs in vitro and vice versa. In addition, RTA, a fragment of Pseudomonas exotoxin A (PE38-lys), and fibronectin also block the binding of the mouse IgG-RTA peptide to ECs, suggesting that an (x)D(y) motif is exposed on all three molecules. Our results suggest that deletions or mutations in this sequence or the use of nondamaging blocking peptides may increase the therapeutic index of both IL-2, as well as ITs prepared with a variety of plant or bacterial toxins.  (+info)

Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia. (2/91)

BACKGROUND: Pulmonary infections are associated with an increase in capillary permeability but information regarding age related differences in the local inflammatory response is lacking. To quantify the degree of capillary leakage during inflammation, the concentrations of the plasma proteins albumin, alpha1-antitrypsin, alpha2-macroglobulin and the locally produced proteins elastase, myeloperoxidase, lactoferrin and fibronectin were studied in the bronchoalveolar lavage (BAL) fluid of immunosuppressed children and adults with pneumonia. METHODS: Sixteen children aged 2-16 years and 15 adults who developed pneumonia while receiving immunosuppressive therapy for haematological malignancies were included in the study. Bronchoalveolar lavage was performed via a flexible bronchoscope with three aliquots of 1 ml/kg body weight in children and 200 ml in adults. Protein concentrations in BAL fluid were determined using highly sensitive immunoluminometric assays. RESULTS: Despite considerable variability, the median concentrations of all proteins in BAL fluid were significantly higher in both patient populations than in previously collected age adjusted reference values. The concentrations of serum derived proteins were significantly higher in children with pneumonia than in adult patients. In contrast, no differences were observed between the two groups for locally produced proteins. CONCLUSIONS: These data suggest that the degree of protein exudation is more pronounced in immunosuppressed children with pneumonia than in adults in a similar clinical situation. This is in agreement with our studies in healthy individuals and may reflect a greater permeability of the alveolar-capillary membrane in children, regardless of disease status.  (+info)

Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. (3/91)

At sites of chronic inflammation seen during infections, autoimmunity, graft-vs-host response, and cytokine therapy, endothelial cell injury is known to occur, the exact mechanism of which is unknown. In the current study we used IL-2-induced vascular leak syndrome (VLS) as a model to investigate whether cytotoxic lymphocytes use CD44 in mediating endothelial cell injury. Administration of IL-2 to wild-type mice triggered significant VLS in the lungs and liver. In contrast, in CD44 knockout (KO) mice, IL-2-induced VLS was markedly reduced in the lungs and liver. IL-2-treated wild-type and CD44 KO mice had similar levels of perivascular infiltration with lymphocytes in the lungs and liver. This suggested that the decrease in VLS seen in CD44 KO mice was not due to the inability of lymphocytes to migrate to these organs. Ultrastructural studies demonstrated extensive endothelial cell damage in the lungs and liver of IL-2-treated wild-type, but not CD44 KO, mice. Moreover, CD44-KO mice exhibited a marked decrease in IL-2-induced lymphokine-activated killer cell activity. The induction of VLS was dependent on the expression of CD44 on immune cells rather than endothelial cells because adoptive transfer of CD44+, but not CD44- spleen cells along with IL-2 into CD44 KO mice triggered VLS. The IL-2-induced VLS was blocked by administration of F(ab')2 of Abs against CD44. The current study demonstrates that CD44 plays a key role in endothelial cell injury. Blocking CD44 in vivo may offer a novel therapeutic approach to prevent endothelial cell injury by cytotoxic lymphocytes in a variety of clinical disease models.  (+info)

Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. (4/91)

Advanced glycation end products (AGEs) are nonenzymatic glycosylated adducts of proteins that accumulate in vascular tissue during diabetes and aging. The aim of this work was to study the role of AGEs and of the oxidative mechanisms in diabetes-induced changes in vascular permeability. Intravital videomicroscopy was used to study albumin microvascular leakage in cremaster muscle. The extravasation of a fluorescent macromolecular tracer (fluorescein isothiocyanate-albumin) was measured for 1 h and, after computer-aided image analysis, was expressed as variations of normalized gray levels (arbitrary units). Extravasation of the macromolecular tracer was much higher in diabetic rats than in control rats (slope of extravasation versus time increased by >100%, P < 10(-4)). This increase was significantly inhibited when we blocked AGEs binding to their endothelial receptor by intravenous bolus of soluble recombinant receptor to AGEs (rR-RAGE) (slope of extravasation versus time decreased by 19, 30, and 40%, for 0.5, 2.5, and 5.15 mg/kg rR-RAGE, respectively) or by a 6 mg/kg intravenous bolus of antibody against RAGE (slope decreased by 53%). Systemic injection of probucol (an antioxidant) also significantly inhibited the increase in the extravasation of the macromolecular tracer occurring in experimental diabetes (slope decreased by 51%, P < 10(-4)). These results strongly suggest that in experimental diabetes the interaction of circulating AGEs and endothelial RAGE mediates albumin micro-vascular leakage, possibly via AGE-RAGE-dependent enhanced oxidant stress.  (+info)

Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation. (5/91)

BACKGROUND: With an incidence of 4%, acute pancreatitis is a common complication of bone marrow or peripheral haematopoietic stem cell transplantation, which contributes significantly to morbidity and mortality in these patients. In most cases, the pathogenesis of acute pancreatitis cannot be attributed to a single pathogenetic factor, as treatment toxicity, acute graft versus host disease, infection, and cholestasis may all contribute. Acute pancreatitis is characterised by inflammation and activation of digestive proenzymes leading to autodigestive destruction of the pancreas and systemic activation of protease cascades including the complement system. AIM: To describe the effects of human C1 esterase inhibitor in two children, who developed severe acute pancreatitis with considerable complement activation after allogeneic haematopoietic stem cell transplantation. METHODS: Both children showed clinical features resembling those observed in capillary leakage syndrome. In both patients, treatment with C1 esterase inhibitor concentrate contributed to a rapid clinical stabilisation. CONCLUSIONS: These observations strongly support the proposed pathophysiological concept that early treatment with C1 esterase inhibitor interferes with the activation of the complement system in acute pancreatitis. Inhibition of complement activation prevents its adverse effects on vascular function and permeability, and thus stabilises intravascular fluid status and prevents multiorgan failure in acute pancreatitis.  (+info)

Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis. (6/91)

BACKGROUND: Capillary leakage with fluid loss into the third space contributes to many of the early systemic complications in severe acute pancreatitis. There has been increasing interest in endothelin as one of the factors affecting capillary permeability. AIM: To elucidate further the role of endothelin in the development of capillary leakage in acute pancreatitis by investigating the effect of exogenous endothelin administration and endothelin receptor blockade in sham operated animals and two models of acute pancreatitis. METHODS: Determination of capillary permeability in the pancreas and colonic mucosa by quantifying extravasation of fluorescein labelled dextran using a novel computer assisted video image analysis system. RESULTS: Pancreatic and colonic capillary permeability increased stepwise from mild to severe acute pancreatitis. Endothelin increased pancreatic and colonic capillary permeability in healthy animals and animals with mild acute pancreatitis but had no additional adverse effect in severe acute pancreatitis. Endothelin receptor blockade decreased pancreatic capillary permeability in sham operated rats but had no effect on the colon. In mild and severe acute pancreatitis, endothelin receptor blockade stabilised increased capillary permeability in both the pancreas and colon. CONCLUSIONS: Endothelin plays an important role in mediating capillary permeability in the pancreas. In severe pancreatitis, it increases capillary permeability even outside the pancreas, thereby contributing to capillary leakage. Endothelin receptor blockade significantly reduces capillary permeability in acute pancreatitis both in and outside the pancreas, suggesting a therapeutic approach to counteract capillary leakage in severe acute pancreatitis.  (+info)

Sensitive blood-retinal barrier breakdown quantitation using Evans blue. (7/91)

PURPOSE: This study investigated whether a nonradioactive dye, Evans blue, can be adapted as a safe alternative to the isotope-dilution method for quantitating blood-retinal barrier breakdown. METHODS: Blood-retinal barrier breakdown was induced in rats with vascular endothelial growth factor (VEGF) or through the induction of diabetes. After allowing Evans blue to circulate in the vasculature, the dye was cleared from the bloodstream with saline, citrate, or citrate-buffered paraformaldehyde, and the efficacies of the perfusion solutions were compared. Extravasated dye was detected at 620 nm and was normalized against the time-averaged Evans blue plasma concentration, the circulation time, and also against wet and dry retina weights. RESULTS: Evans blue leakage from retinas treated with VEGF was 4.0-fold higher than that of contralateral untreated eyes (n = 6 rats, P: < 0.05). Retinal Evans blue leakage of eyes from 1-week diabetic animals (n = 11 retinas) was 1.7-fold higher (P: < 0.05) than that of nondiabetic controls (n = 10 retinas). Intra-animal, inter-retina weights showed significantly less variability (P: < 0.05) with the use of dry weights (11.2%, n = 74 retina pairs) than with wet weights (20.5%, n = 93 retina pairs). CONCLUSIONS: The Evans blue dye technique can be modified to be as sensitive and quantitative as the isotope-dilution method for measuring blood-retinal barrier breakdown. The advantages of the Evans blue technique are its safety, relative simplicity, and economy.  (+info)

The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. (8/91)

A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.  (+info)

Capillary leak syndrome (CLS) is a rare, but serious condition characterized by the abnormal leakage of plasma from the bloodstream into surrounding tissues. This occurs due to increased permeability of the capillary walls, which are the smallest blood vessels in the body that connect arterioles and venules, allowing for the exchange of nutrients, waste products, and gases between the blood and the tissues.

In CLS, the leakage of plasma leads to a rapid loss of intravascular volume, resulting in hypotension (low blood pressure), hemoconcentration (increased concentration of red blood cells due to reduced plasma volume), and edema (swelling) in various parts of the body. The fluid shift from the bloodstream to the tissues can also cause organ dysfunction and failure if not promptly treated.

The exact causes of capillary leak syndrome are not fully understood, but it can be associated with certain medical conditions, such as infections, autoimmune disorders, medications, or cancer. In some cases, CLS may occur without an identifiable underlying cause, known as idiopathic capillary leak syndrome.

Treatment for capillary leak syndrome typically involves supportive care to maintain blood pressure, replace lost fluids and electrolytes, and manage any organ dysfunction. Medications such as corticosteroids, immunoglobulins, or vasopressors may be used depending on the severity of the condition and the presence of underlying causes. In severe cases, extracorporeal membrane oxygenation (ECMO) or other intensive care interventions might be necessary to support organ function and ensure adequate blood flow.

Capillary permeability refers to the ability of substances to pass through the walls of capillaries, which are the smallest blood vessels in the body. These tiny vessels connect the arterioles and venules, allowing for the exchange of nutrients, waste products, and gases between the blood and the surrounding tissues.

The capillary wall is composed of a single layer of endothelial cells that are held together by tight junctions. The permeability of these walls varies depending on the size and charge of the molecules attempting to pass through. Small, uncharged molecules such as water, oxygen, and carbon dioxide can easily diffuse through the capillary wall, while larger or charged molecules such as proteins and large ions have more difficulty passing through.

Increased capillary permeability can occur in response to inflammation, infection, or injury, allowing larger molecules and immune cells to enter the surrounding tissues. This can lead to swelling (edema) and tissue damage if not controlled. Decreased capillary permeability, on the other hand, can lead to impaired nutrient exchange and tissue hypoxia.

Overall, the permeability of capillaries is a critical factor in maintaining the health and function of tissues throughout the body.

Hairy cell leukemia (HCL) is a rare, slow-growing type of cancer in which the bone marrow makes too many B cells (a type of white blood cell). These excess B cells are often referred to as "hairy cells" because they look abnormal under the microscope, with fine projections or "hair-like" cytoplasmic protrusions.

In HCL, these abnormal B cells can build up in the bone marrow and spleen, causing both of them to enlarge. The accumulation of hairy cells in the bone marrow can crowd out healthy blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia). This can result in fatigue, increased risk of infection, and easy bruising or bleeding.

HCL is typically an indolent disease, meaning that it progresses slowly over time. However, some cases may require treatment to manage symptoms and prevent complications. Treatment options for HCL include chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. Regular follow-up with a healthcare provider is essential to monitor the disease's progression and adjust treatment plans as needed.

Siglec-2, also known as CD22, is a type of cell surface protein that belongs to the sialic acid-binding immunoglobulin-like lectins (Siglecs) family. It is primarily expressed on mature B cells and plays a crucial role in regulating B cell activation and function. Siglec-2 recognizes and binds to sialic acid residues on glycoproteins and gangliosides, which are sugars that are attached to proteins and lipids on the surface of cells. This binding can lead to inhibitory signals that dampen B cell activation and help prevent autoimmunity. Siglec-2 has also been implicated in the regulation of B cell migration and adhesion.

"Drug approval" is the process by which a regulatory agency, such as the US Food and Drug Administration (FDA), grants formal authorization for a pharmaceutical company to market and sell a drug for a specific medical condition. The approval process is based on rigorous evaluation of clinical trial data to ensure that the drug is safe and effective for its intended use.

The FDA's approval process typically involves several stages, including preclinical testing in the lab and animal studies, followed by three phases of clinical trials in human subjects. The first phase tests the safety of the drug in a small group of healthy volunteers, while the second and third phases test the drug's efficacy and side effects in larger groups of patients with the medical condition for which the drug is intended.

If the results of these studies demonstrate that the drug is safe and effective, the pharmaceutical company can submit a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for review. The application includes data from the clinical trials, as well as information about the manufacturing process, labeling, and proposed use of the drug.

The FDA reviews the application and may seek input from independent experts before making a decision on whether to approve the drug. If approved, the drug can be marketed and sold to patients with the medical condition for which it was approved. The FDA continues to monitor the safety and efficacy of approved drugs after they reach the market to ensure that they remain safe and effective for their intended use.

Cladribine is a medication used in the treatment of certain types of cancer and multiple sclerosis. It is a type of drug called a purine nucleoside analog, which means it interferes with the production of DNA and RNA, the genetic material of cells. This can help to stop the growth and multiplication of abnormal cells in the body.

In cancer treatment, cladribine is used to treat hairy cell leukemia and certain types of lymphoma. In multiple sclerosis, it is used to reduce the frequency of relapses and slow down the progression of disability. Cladribine works by selectively targeting and depleting certain white blood cells called lymphocytes, which are thought to play a role in the immune response that damages the nervous system in multiple sclerosis.

Cladribine is usually given as an injection into a vein or under the skin, and it may be given on its own or in combination with other medications. Common side effects of cladribine include nausea, vomiting, diarrhea, and weakness. It can also lower the body's ability to fight infections, so patients may need to take precautions to avoid infection while receiving treatment. Cladribine should be used with caution in people with a history of certain medical conditions, such as liver or kidney disease, and it should not be used during pregnancy or breastfeeding.

The United States Food and Drug Administration (FDA) is a federal government agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our country's food supply, cosmetics, and products that emit radiation. The FDA also provides guidance on the proper use of these products, and enforces laws and regulations related to them. It is part of the Department of Health and Human Services (HHS).

Pentostatin is a medication used in the treatment of certain types of cancer, including hairy cell leukemia and certain T-cell lymphomas. It is a type of drug called a purine nucleoside analog, which works by interfering with the production of DNA and RNA, the genetic material found in cells. This can help to stop the growth and multiplication of cancer cells.

Pentostatin is given intravenously (through an IV) in a healthcare setting, such as a hospital or clinic. It is usually administered on a schedule of every other week. Common side effects of pentostatin include nausea, vomiting, diarrhea, and loss of appetite. It can also cause more serious side effects, such as low blood cell counts, infections, and liver problems.

It's important to note that this is a medical definition of the drug and its use, and it should not be used as a substitute for professional medical advice. If you have any questions about pentostatin or your treatment, it is best to speak with your healthcare provider.

"Device approval" is a term used to describe the process by which a medical device is determined to be safe and effective for use in patients by regulatory authorities, such as the U.S. Food and Drug Administration (FDA). The approval process typically involves a rigorous evaluation of the device's design, performance, and safety data, as well as a review of the manufacturer's quality systems and labeling.

The FDA's Center for Devices and Radiological Health (CDRH) is responsible for regulating medical devices in the United States. The CDRH uses a risk-based classification system to determine the level of regulatory control needed for each device. Class I devices are considered low risk, Class II devices are moderate risk, and Class III devices are high risk.

For Class III devices, which include life-sustaining or life-supporting devices, as well as those that present a potential unreasonable risk of illness or injury, the approval process typically involves a premarket approval (PMA) application. This requires the submission of comprehensive scientific evidence to demonstrate the safety and effectiveness of the device.

For Class II devices, which include moderate-risk devices such as infusion pumps and powered wheelchairs, the approval process may involve a premarket notification (510(k)) submission. This requires the manufacturer to demonstrate that their device is substantially equivalent to a predicate device that is already legally marketed in the United States.

Once a medical device has been approved for marketing, the FDA continues to monitor its safety and effectiveness through post-market surveillance programs. Manufacturers are required to report any adverse events or product problems to the FDA, and the agency may take regulatory action if necessary to protect public health.

Capillary leak syndrome, or vascular leak syndrome, is characterized by the escape of blood plasma through capillary walls, ... Systemic capillary leak syndrome (SCLS), also called Clarksons disease, or primary capillary leak syndrome, is a rare, grave ... can also cause capillary leaks. These conditions and factors are sources of secondary capillary leak syndrome. ... engraftment syndrome, hemophagocytic lymphohistiocytosis, the ovarian hyperstimulation syndrome, viral hemorrhagic fevers, and ...
Capillary leak syndrome (‏CLS)‏ has been described in dengue fever but its exact features have not been clearly defined. We ... Capillary leak syndrome in dengue fever.. dc.contributor.author. Verma, Sudhir Kumar. ... Capillary leak syndrome in dengue fever. Dengue Bulletin. 2011 Dec; 35: 65-70.. EN. ... Capillary leak syndrome. EN. dc.title. Capillary leak syndrome in dengue fever.. EN. ...
Capillary leak syndrome (‎CLS)‎ has been described in dengue fever but its exact features have not been clearly defined. We ... Capillary leak syndrome in dengue fever. Dengue Bulletin. 2011 Dec; 35: 65-70. ... 2011)‎. Capillary leak syndrome in dengue fever.. WHO Regional Office for South-East Asia.. https://extranet.who.int/iris/ ...
Fatal Exacerbations of Systemic Capillary Leak Syndrome Complicating Coronavirus Disease Patricia C. Cheung, A. Robin Eisch, ... Fatal Exacerbations of Systemic Capillary Leak Syndrome Complicating Coronavirus Disease. ... systemic capillary leak syndrome; TNF, tumor necrosis factor. ...
The enigmatic systemic capillary leak syndrome (SCLS) named for Dr Clarkson is characterized by transient a … ... Plasma from an acute attack induced a shock-like syndrome when injected into rats. ... Idiopathic systemic capillary leak syndrome (Clarkson disease) Kirk M Druey et al. J Allergy Clin Immunol. 2017 Sep. ... Idiopathic systemic capillary leak syndrome (Clarkson disease) Kirk M Druey 1 , Samir M Parikh 2 ...
Capillary leak syndrome (CLS) is a rare disease with profound vascular leakage, which can be associated with a high mortality. ... All study patients developed capillary leak syndrome after receiving anti-cancer agents. There were no capillary leak syndrome ... Capillary leak syndrome (CLS), also known as vascular leak syndrome (VLS), is a rare but fatal disease, and an idiopathic form ... Systemic Capillary Leak Syndrome (Clarkson Syndrome) in Cancer Patients: A Systematic Review. J. Clin. Med. 2018, 7, 418. [ ...
In this case, we report a child with refractory acute lymphoblastic leukemia who developed fatal capillary leak syndrome during ... Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia Birol Baytan 1 , Ozlem ... Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia Birol Baytan et al. J ... Anticancer Drug-Induced Capillary Leak Syndrome. Izzedine H, Mathian A, Amoura Z, Ng JH, Jhaveri KD. Izzedine H, et al. Kidney ...
Systemic capillary leak syndrome (Clarksons disease) / Kirk Druey. Author: Levine, Stewart J. National Institutes of Health (U ... CC Grand Rounds: (1) Developing New Therapeutic Strategies for Severe Asthma (2) Systemic Capillary Leak Syndrome (Clarksons ... CC Grand Rounds: (1) Developing New Therapeutic Strategies for Severe Asthma (2) Systemic Capillary Leak Syndrome (Clarksons ...
Systemic capillary leak syndrome (SCLS) is a rare and potentially fatal vascular disorder characterized by reversible bouts of ... Endothelial expression of endothelin receptor A in the systemic capillary leak syndrome. Thursday, September 17, 2015. - Poster ... Further studies of the ET-1-ETA axis in SCLS and in more common plasma leakage syndromes such as sepsis would advance our ...
"Capillary Leak Syndrome" by people in UAMS Profiles by year, and whether "Capillary Leak Syndrome" was a major or minor topic ... "Capillary Leak Syndrome" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Capillary Leak Syndrome" by people in Profiles over the past ten years. ... Below are MeSH descriptors whose meaning is more general than "Capillary Leak Syndrome". ...
The European Medicines Agency has started a review of safety signals in regard to capillary leak syndrome with the AstraZeneca ... Capillary Leak Syndrome with AZ Vaccine An EMA press release issued today notes that five cases of capillary leak syndrome, ... meeting April 6-9 include that the agency has started a review of a safety signal to assess reports of capillary leak syndrome ... it is not yet clear whether there is a causal association between vaccination and the reports of capillary leak syndrome. These ...
NCPE / capillary leak syndrome. A variety of drugs can cause NCPE. This is a less common pattern of drug-induced involvement ... In severe cases, this syndrome may lead to capillary leakage, renal and hepatic dysfunction, and cardiopulmonary compromise. [ ... This, in turn, leads to a hypoxic effect on the alveolar capillary membrane, resulting in increased capillary permeability. ... Acute chest pain syndrome during bleomycin infusions. Cancer. 1987 May 1. 59 (9):1582-5. [QxMD MEDLINE Link]. ...
Capillary Leak Syndrome. Capillary leak syndrome, a potential manifestation of retinoic acid syndrome, has been reported in ... Rhabdomyolysis and myalgias have been reported in association with capillary leak syndrome, and laboratory tests may reveal ... Features of this syndrome may include localized or generalized edema with secondary weight gain, fever, and hypotension. ... Acitretin capsules can cause fluid to leak out of your blood vessels into your body tissues. Call your prescriber right away if ...
Studies continue to be done to understand the relationship between monoclonal IgG gammopathy and Capillary leak syndrome.[1] ... The relationship between Capillary leak syndrome and post-episodic levels of monoclonal IgG are of interest and continue to be ... Risk calculators and risk factors for Capillary leak syndrome future or investigational therapies ... American Roentgen Ray Society Images of Capillary leak syndrome future or investigational therapies ...
Fatal Exacerbations of Systemic Capillary Leak Syndrome Complicating Coronavirus Disease Patricia C. Cheung, A. Robin Eisch, ... Fatal Exacerbations of Systemic Capillary Leak Syndrome Complicating Coronavirus Disease. ... systemic capillary leak syndrome; TNF, tumor necrosis factor. ...
... has concluded that people who have previously had capillary leak syndrome must not be vaccinated with Vaxzevria (formerly ... Capillary leak syndrome is a very rare, serious condition that causes fluid leakage from small blood vessels (capillaries), ... The Committee carried out an in-depth review of 6 cases of capillary leak syndrome in people who had received Vaxzevria.1 Most ... Three of those affected had a history of capillary leak syndrome and one of them subsequently died. As of 27 May 2021, more ...
Sézary Syndrome with Capillary Leak Syndrome Open the PDF for ,span class=search-highlight,Biclonal,/span, Sézary Syndrome ... O. Dereure; P. Portales; J. Clot; J.J. Guilhou Sézary syndrome is a rare, usually monoclonal proliferation of T lymphoid cells ...
systemic capillary leak syndrome. yes. Duffy, Patrick Emmet, M.D.. NIAID. malaria. N/A. ... chronic graft versus host disease, hematologic malignancies, myelodysplastic syndromes, acute myelogenous leukemia. yes. ... pathophysiology and treatment of neuroinflammatory syndromes in refractory fungal infections. N/A. ...
Capillary leak syndrome. *Capillary leak syndrome reported and characterized by hypotension, hypoalbuminemia, edema, and ... Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been associated with rhG-CSF products in conjunction with ... Acute respiratory distress syndrome (ARDS) can occur; evaluate patients who develop fever and lung infiltrates or respiratory ...
Diagnosis or suspected diagnosis of Systemic Capillary Leak Syndrome by a physician or documented history of capillary leak as ... Systemic Capillary Leak Syndrome (SCLS) is a disorder of unknown cause characterized by episodes of life-threatening drop in ... Cicardi M, Gardinali M, Bisiani G, Rosti A, Allavena P, Agostoni A. The systemic capillary leak syndrome: appearance of ... Studies in the Pathogenesis of Systemic Capillary Leak Syndrome. This study is currently recruiting participants. ...
5.7 Capillary Leak Syndrome. Capillary leak syndrome (CLS) has been reported after G-CSF administration, including filgrastim ... 5.7 Capillary Leak Syndrome 5.8 Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) 5.9 Thrombocytopenia 5.10 ... Capillary leak syndrome. RELEUKO can cause fluid to leak from blood vessels into your bodys tissues. This condition is called ... Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment ...
Systemic capillary leak syndrome after SARS-CoV-2 infection and after COVID-19 vaccination: A scoping review in relation to a ... Systemic capillary leak syndrome after SARS-CoV-2 infection and after COVID-19 vaccination: A scoping review in relation to a ... Table 1. Characteristics of systemic capillary leak syndrome (SCLS) in cases (with SARS-CoV-2 infection or COVID-19 vaccination ... June - July 2022 Systemic capillary leak syndrome after SARS-CoV-2 infection and after COVID-19... ...
Capillary leak syndrome is a rare disorder that causes a dramatic drop in blood pressure. Early diagnosis is important to ... leaking of the fluid that surrounds the brain. Your child may also be at a slightly increased risk of developing skin ... Sometimes microtia appears alongside other craniofacial syndromes, or as part of them. If the pediatrician suspects this, your ...
Capillary leak syndrome may occur immediately after aldesleukin is given. If you experience any of the following symptoms, tell ... Aldesleukin may cause a severe and life-threatening reaction called capillary leak syndrome (a condition that causes the body ...
Boxed WARNING: CAPILLARY LEAK SYNDROME. *Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in ... Capillary Leak Syndrome. Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among ... Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and ...
Boxed WARNING: CAPILLARY LEAK SYNDROME. *Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in ... Capillary Leak Syndrome. Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among ... Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and ...
Capillary leak syndrome. Very rare cases of capillary leak syndrome (CLS) have been reported following vaccination with ... If you have a previous diagnosis of capillary leak syndrome (a condition causing fluid leakage from small blood vessels). ... capillary leak syndrome (a condition causing fluid leakage from small blood vessels) ... If you previously had Guillain-Barré syndrome (temporary loss of feeling and movement) or Transverse Myelitis (inflammation of ...
No capillary leak syndrome or cytokine release syndrome are reported. * Discontinuations due to pivekimab-related adverse ... "With promising anti-tumor activity, manageable safety including no observed capillary leak or cytokine release syndrome, and ...
Rare (less than 0.1%): Brain-capillary leak syndrome (reversible posterior hyponatremia hypertensive encephalopathy ... The syndrome can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. ... Charles Bonnet syndrome (visual hallucinations) after intravitreal avastin injection for age-related macular degeneration. Am J ... 7. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007; ...

No FAQ available that match "capillary leak syndrome"